Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZN-e4 |
| Synonyms | |
| Therapy Description |
ZN-e4 is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including T790M, potentially leading to tumor regression (Cancer Res (2021) 81 (13_Supplement): 2423). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZN-e4 | ZNe4|ZN e4|KP-673 | EGFR Inhibitor 3rd gen 28 | ZN-e4 is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including T790M, potentially leading to tumor regression (Cancer Res (2021) 81 (13_Supplement): 2423). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03446417 | Phase I | ZN-e4 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | Completed | USA | 1 |